CNS Biomarkers: Monument Targets Schizophrenia, Anxiety And Cognitive Decline
An Interview With Steven Powell
Executive Summary
Steven Powell, chair of the board at Cambridge Cognition, talks about the group’s latest spin-off company, Monument Therapeutics.
You may also be interested in...
Internal Manufacturing Capabilities Are Critical To Level-Up eTheRNA
A year into his role as a CEO of the Belgian mRNA biotech eTheRNA immunotherapies, industry veteran Steven Powell talks to In Vivo about his plans for the business over the coming couple of years. An important timeframe to move the company well into clinical activity.
Biotech Foundations: Networks And Lab Space Are As Crucial As Funding
BioInnovation Institute chief business officer Bobby Soni shares how the life sciences incubator sources entrepreneurs and science globally, and the range of tools it provides to translate this into commercially viable companies.
Lithuania Caps Off Decade Of Growth With Stellar 2020
Lithuania’s life sciences sector has harnessed the country’s talent, infrastructure and government support to realize a decade of unprecedented growth. With the industry now maturing, can the Baltic state overcome challenges to become a significant European player?